Uric acid, the metabolic product of purines, relies on xanthine oxidase (XOD) for production. XOD is a target for the development of drugs for hyperuricemia (HUA) and gout. Currently, treatment options remain limited for gout patients. 3, 4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a derivative of the natural product protocatechualdehyde with good biological activity. In this work, we identify a DHNB thiosemicarbazide class of compounds that targets XOD. 3,4-Dihydroxy-5-nitrobenzaldehyde phenylthiosemicarbazone can effectively inhibit XOD activity (IC50 value: 0.0437 μM) and exhibits a mixed inhibitory effect. In a mouse model of acute hyperuricemia, a moderate dose (10 mg/kg.w) of 3,4-dihydroxy-5-nitrobenzaldehyde phenylthiosemicarbazide effectively controlled the serum uric acid content and significantly inhibited serum XOD activity. In addition, 3,4-Dihydroxy-5-nitrobenzaldehyde phenylthiosemicarbazide showed favorable safety profiles, and mice treated with the target compound did not show any symptoms of general toxicity following a single dose of 500 mg/kg. In the allopurinol group, 50 % of the mice died. These results provide a structural framework and mechanism of XOD inhibition that may facilitate the design of hyperuricemia and gout treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejps.2024.106778 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Nanosized Porous Supramolecular Lead(II)-'-phenyl(pyridin-2-yl)methylene--phenylthiosemicarbazide Aggregate, Obtained Under Electrochemical Conditions.
Inorg Chem
October 2024
University of Tyumen, Volodarskogo Str. 6, Tyumen 625003, Russian Federation.
A novel nanosized porous supramolecular nonanuclear complex [Pb(HL)Cl(ClO)](ClO)·15HO(solvent) (·15HO(solvent)) is reported that was synthesized by electrochemical oxidation of a Pb anode under the ambient conditions in a CHCN:MeOH solution of '-phenyl(pyridin-2-yl)methylene--phenylthiosemicarbazide (), containing [N(CH)]ClO as a current carrier. The supramolecular aggregate of is enforced by a myriad of Pb···S tetrel bonds (TtBs) established with the thiocarbonyl sulfur atoms of adjacent species, which have been also analyzed by DFT calculations via 2D maps of ELF, Laplacian and RDG properties. Moreover, Pb···Cl TtBs with the central Cl anion, and Pb···O TtBs with the three oxygen atoms of the ClO anion, were revealed.
View Article and Find Full Text PDFThiazolation of phenylthiosemicarbazone to access new thiazoles: anticancer activity and molecular docking.
Future Med Chem
July 2024
Department of Chemistry, Faculty of Science, Arish University, Arish, 45511, Egypt.
Novel thiazole hybrids were synthesized via thiazolation of 4-phenylthiosemicarbazone (). The anticancer activity against the NCI 60 cancer cell line panel. Methyl 2-(2-((1-(naphthalen-2-yl)ethylidene)hydrazineylidene)-4-oxo-3-phenylthiazolidin-5-ylidene)acetate () showed significant anticancer activity at 10 μM with a mean growth inhibition (GI) of 51.
View Article and Find Full Text PDFA potential therapeutic agent for the treatment of hyperuricemia and gout: 3,4-Dihydroxy-5-nitrobenzaldehyde phenylthiosemicarbazide.
Eur J Pharm Sci
July 2024
College of Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China. Electronic address:
Uric acid, the metabolic product of purines, relies on xanthine oxidase (XOD) for production. XOD is a target for the development of drugs for hyperuricemia (HUA) and gout. Currently, treatment options remain limited for gout patients.
View Article and Find Full Text PDFNew phenylthiosemicarbazide-phenoxy-1,2,3-triazole-N-phenylacetamides as dual inhibitors against α-glucosidase and PTP-1B for the treatment of type 2 diabetes.
Arch Pharm (Weinheim)
July 2024
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- This study focuses on creating and testing new phenylthiosemicarbazide-phenoxy-1,2,3-triazole-N-phenylacetamide compounds (7a-l) as potential treatments for type 2 diabetes by inhibiting two key enzymes: α-glucosidase and protein tyrosine phosphatase 1-B (PTP-1B).
- All tested compounds (7a-l) showed stronger inhibition of α-glucosidase compared to acarbose, a standard drug, while only some (7a, 7g, 7h, and 7i) outperformed suramin against PTP-1B.
- The most effective inhibitors identified were compound 7i for
New Organotin (IV) Compounds Derived from Dehydroacetic Acid and Thiosemicarbazides: Synthesis, Rational Design, Cytotoxic Evaluation, and Molecular Docking Simulation.
Bioinorg Chem Appl
October 2023
Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior S/N, Ciudad Universitaria, Alcaldía Coyoacán, C. P. 04510, Ciudad de México, Mexico.
Organotin complexes were prepared through a one-pot reaction with three components by reacting thiosemicarbazide or 4-methyl-3-thiosemicarbazide or 4-phenylthiosemicarbazide, dehydroacetic acid (DHA) and dibutyl, diphenyl, dicyclohexyl, and bis[(trimethylsilyl)methyl]tin(IV) oxides; all complexes were characterized by infrared (IR), ultraviolet-visible (UV-vis), mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy. The Sn NMR revealed chemical shifts corresponding to a pentacoordinated environment in solution. The X-ray crystallography of the two complexes evidenced the formation of monomeric complexes with a pentacoordinated geometry around tin via three donor atoms from the ligand, the sulfur of the thiol, the nitrogen of the imine group, and the oxygen of the pyran ring.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!